$COR

Cencora, Inc. (COR): Entry into a Material Definitive Agreement

Cencora, Inc. (COR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 3 tm2621845d1_ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 EXECUTION VERSION OMNIBUS AMENDMENT This OMNIBUS AMENDMENT, dated as of July 31, 2026 (this “ Amendment ”) is (1) THE TWENTY-THIRD AMENDMENT TO AMENDED AND RESTATED RECEIVABLES PURCHASE AGREEMENT, among AMERISOURCE RECEIV

Original reporting
Published Aug 5, 2026, 10:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 11:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$COR
Neutral
medium confidence
Mentioned
$COR
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CORNeutralLow
01

Why it matters

The amendment adds BBVA as a purchaser party and adjusts purchase limits, while Cencora remains the performance guarantor under the amended performance undertaking.

02

Market read

This is a financing-structure amendment disclosed via SEC 8-K, potentially relevant to credit-risk and funding-cost expectations, but the excerpt lacks quantified terms.

03

What to watch

Traders may need the full exhibits (fee letter and amended purchase limits) to assess whether guarantee exposure or funding costs changed meaningfully.

Relevance 6/10Novelty 5/10Timing: filed pre-market today (2026-08-05)

Background

The 8-K is an Item 1.01 disclosure for entry into a material definitive agreement, with Item 2.03 covering creation of a direct financial obligation or off-balance-sheet obligation.

Company-level read

Ticker impact

$CORNeutralMedium confidence
Context

Cencora disclosed an 8-K entry into a material definitive agreement, amending its receivables purchase and performance undertaking obligations.

Expected impact

Likely limited near-term impact unless the full exhibit details materially change purchase limits, fees, or guarantee exposure.

Evidence & confidence

The excerpt confirms a material definitive agreement and amendments, including BBVA joinder and changes to purchase limits, but provides no figures or credit-spread/fee changes.

Market effects

Highlights ongoing use of receivables purchase facilities and performance undertakings in healthcare distribution financing structures.

None indicated beyond involvement of BBVA and MUFG as counterparties.

None indicated; transaction appears to be a financing-structure amendment rather than cross-border operating change.

Counterpoint

Because the excerpt does not show any change in Cencora’s operating outlook or guarantee economics, the market may treat this as routine documentation rather than a risk event.

Key entities

  • Cencora, Inc.

    Performance guarantor in the amended receivables purchase and performance undertaking agreements disclosed on Form 8-K.

  • BBVA

    Joins as an uncommitted and related committed purchaser and purchaser agent under the receivables purchase agreement.

  • MUFG Bank, Ltd.

    Administrator for the receivables purchase agreement and related transaction documents.

Related articles

$CORMed

The Bull Case For Cencora (COR) Could Change Following Raised EPS Outlook And Bigger Buybacks And Dividend

Cencora (COR) reported Q3 2026 sales of $84.75B and net income of $763.5M, and amended credit and receivables facilities, expanding revolving capacity to $7.0B. The company raised its fiscal 2026 adjusted EPS outlook, completed a $2.0B buyback tranche, and declared a $0.60 quarterly dividend. It flagged a possible earnings headwind tied to an MWI Animal Health-Covetrus merger.

$CORMedAI 8/10

Cencora Q3 Earnings Call Highlights

Cencora (NYSE:COR) reported Q3 results on its earnings call. U.S. Healthcare Solutions operating income rose 16% to $966 million, and International revenue grew 6% to $7.7 billion with operating income up 21% to $166 million. The company expects fiscal 2026 consolidated adjusted operating income growth of 13% to 14%, and said OneOncology integration is modestly ahead of initial expectations.

$CORMed

Cencora, Inc. Q3 2026 Earnings Call Summary

Cencora reported Q3 2026 results driven by specialty pharmaceutical strength in health systems and physician practices, with its MSO platforms (including OneOncology and RCA) ahead of expectations. Adjusted EPS guidance for fiscal 2026 was raised to $17.75 to $17.95. The company completed $1 billion of share repurchases, expects U.S. Healthcare Solutions revenue in the lower half of 4% to 6% growth, and cited a $0.35 EPS headwind from the pending MWI Animal Health merger.

$CORHigh

Cencora, Inc. (COR): Results of Operations and Financial Condition

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q32026.htm EX-99.1 Document Exhibit 99.1 CENCORA REPORTS FISCAL 2026 THIRD QUARTER RESULTS Revenue of $84.8 billion for the Third Quarter, a 5.1 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.94 and Adjusted Diluted EPS of $4.48 Adjusted